Search filters
Filters
Clear All

Phase

  • 183
  • 156
  • 2
  • 194
  • 1
  • 148
  • 17
  • 396
  • 1237
  • 588
  • 29
  • 49
  • 3
  • 1162
  • 1237
  • 6
  • 3
  • 1240

Found 1243 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

UPCC 04423: Expanded Access Program for belantamab mafodotin in Patients with Relapsed/Refractory Multiple Myeloma who are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and an Anti-CD38 Antibody

99 years or below
All genders
Compassionate use access to belantamab mafodotin (GSK2857916) for eligible participants with refractory/relapsing multiple myeloma. We would like to rely on WCG as the IRB of record for this study.
Learn More

Intraoperative electrophysiological recording in patients undergoing brain surgery

99 years or below
All genders
The purpose of this protocol is to allow for intraoperative electrophysiological recording from patients already scheduled to undergo a craniotomy that will expose the cerebral cortex. During surgery, a recording array will be briefly placed on the surface of the brain and signals will be recorded while the patient is …
Learn More

Identification of culturally responsive and unresponsive mental healthcare

99 years or below
All genders
Systemic and interpersonal discrimination has led to Black, Indigenous, and People of Color and lesbian, gay, bisexual, transgender, and queer individuals facing high rates of psychological distress. We will use a mixed methods design to gain rich contextual information on therapist behaviors and relational processes informing culturally responsive and unresponsive …
Learn More

UPCC 33922: An Open-Label Multicenter Study of LOXO-435 (LY3866288) In Advanced Solid Tumor Malignancies With FGFR3 Alterations

99 years or below
All genders
Phase 1
Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints) Please refer to Protocol LOXO-FG3-22001, Section 1.1.1 (Objectives and Endpoints)
Learn More

UPCC 32422 A Phase 1-2 Open-Label Study of the Safety Pharmacokinetics Pharmacodynamics and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/Cedazuridine and Oral Decitabine/Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma

99 years or below
All genders
The primary purpose of the study is to assess safety, and to identify the recommended phase 2 dose (RP2D) of tolinapant in combination with oral decitabine/cedazuridine in Phase 1 and to assess preliminary efficacy as determined by overall response rate (ORR) in Phase 2.
Learn More

UPCC 35922: Phase 1/2 Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

99 years or below
All genders
Phase 1
Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints) Please see Protocol NUV-868-01, Section 3 (Objectives and Endpoints)
Learn More

UPCC 52422: A Phase 1 Multicenter Open-Label Dose-Escalation and Expansion Study to Evaluate the Safety Tolerability Pharmacokinetics Pharmacodynamics and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas Large Granular Lymphocytic Leukemia and Solid Tumors

99 years or below
All genders
Phase 1
Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints) Please refer to Protocol Section 2 (Objectives and Endpoints)
Learn More

Uncovering the etiologies of non-immune hydrops fetalis through comprehensive genomic analyses and phenotyping

99 years or below
Female
The goal of this study is to better understand the genetic causes of non-immune hydrops fetalis (NIHF) and other types of abnormal fluid collections with genomic sequencing, detailed review of clinical information, and in some cases, additional research testing. As NIHF and other types of abnormal fluid collections are often …
Learn More

UPCC 28921: A Phase I/IIa Open-label Multi-centre Study to Assess the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumours

99 years or below
All genders
This study has a mono therapy arm and a combination therapy arm. The main purpose of the mono therapy arm is to test the safety and tolerability of ART4215 in humans. The main purpose of the combination therapy arm is to test ART4215 compared to and in combination with talazoparib.
Learn More

UPCC 39422 Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene autoleucel (cilta-cel) Out-of-Specification (OOS) in patients with Multiple Myeloma

99 years or below
All genders
he purpose of this expanded access program (EAP) is to provide ciltacabtagene autoleucel (cilta-cel) that does not meet the commercial release specifications of CARVYKTI and is not available via the local health care system in the country where the treatment is requested.
Learn More
1171 - 1180 of 1243